Pembrolizumab with or without Paclitaxel or Irinotecan in Treating Patients with Locally Advanced or Metastatic High Grade Neuroendocrine Cancer

Status: Active

Description

This phase II clinical trial studies how well pembrolizumab with or without paclitaxel or irinotecan works in treating patients with high grade neuroendocrine cancer that has spread to nearby tissues or lymph nodes or other places in the body. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as paclitaxel and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with or without paclitaxel or irinotecan hydrochloride may work better in treating patients with neuroendocrine cancer.

Eligibility Criteria

Inclusion Criteria

  • Be willing and able to provide written informed consent for the trial
  • Have a histologically proven locally advanced or metastatic high grade (G3) poorly differentiated neuroendocrine carcinoma (NEC) * Includes small cell and large cell neuroendocrine carcinoma of unknown primary or any extrapulmonary site (and poorly differentiated NEC, not otherwise specified) * Includes neuroendocrine prostate cancer (de novo or treatment-emergent) of prostate if small cell or large cell histology (histologic evidence of both adenocarcinoma and neuroendocrine carcinoma may be present in same patient) * Other mixed tumors, e.g. mixed neuroendocrine neoplasms (MINENs) with NEC plus adenocarcinoma, squamous or acinar cell component are allowed if the high grade (small or large cell) NEC component comprises > 50% of the original sample or subsequent biopsy
  • Have progressed during or after completion of first line systemic chemo therapy * No limit to the number of prior chemotherapy regimens * Early progression on/after adjuvant chemotherapy counts as first-line therapy
  • Have at least one measurable disease based on RECIST 1.1
  • Patients must agree to have a biopsy of primary tumor or metastatic tissue at baseline, and there must be a lesion that can be biopsied with acceptable clinical risk (as judged by the investigator) * Patients with unsuccessful baseline biopsies may undergo an additional biopsy attempt (at the same or a different site, determined by the investigator) * For patients with an intact primary and no metastatic site that can be safely biopsied, biopsy of the primary is acceptable, but must be approved by the principal investigator * Baseline tumor biopsy may be omitted if the tumor is inaccessible and/or a biopsy is not thought to post exceptionally high procedural risk due to location or other factors
  • Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale
  • Have a life expectancy of greater than 3 months
  • Absolute neutrophil count (ANC) >= 1,500 /mcL (within 14 days of treatment initiation)
  • Platelets >= 100,000/mcL (within 14 days of treatment initiation)
  • Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment) (within 14 days of treatment initiation)
  • Serum creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 60 mL/min for subject with creatinine levels > 1.5 x institutional ULN (within 14 days of treatment initiation)
  • Serum total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for subjects with total bilirubin levels > 1.5 ULN (within 14 days of treatment initiation)
  • Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) alanine aminotransaminase (ALT) serum glutamate pyruvate transaminase (SGPT) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases (within 14 days of treatment initiation)
  • Albumin >= 2.5 mg/dL (within 14 days of treatment initiation)
  • International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants (within 14 days of treatment initiation)
  • Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants (within 14 days of treatment initiation)
  • Female subject of childbearing potential should have a negative urine or serum pregnancy within 14 days prior to receiving the first dose of study medication; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication; subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
  • Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy; NOTE: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject

Exclusion Criteria

  • Has Merkel cell carcinoma, small cell lung carcinoma, or large cell NEC of lung * Intermediate grade neuroendocrine tumors are excluded * Well differentiated grade 3 neuroendocrine tumors are excluded * Metastatic high-grade prostate carcinoma with evidence of focal neuroendocrine differentiation on prostate biopsy (e.g., positive chromogranin staining by immunohistochemistry) without small cell or large cell NEC morphology are excluded, as are neuroendocrine prostate cancers with phenotype intermediate between adenocarcinoma and small cell * Atypical bronchial carcinoid and well differentiated G2 gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) are excluded
  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment
  • Has a diagnosis of immunodeficiency
  • Is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment * Physiologic doses of steroids (e.g. =< 10 mg prednisone/day or equivalent) are allowed; topical, inhaled, nasal and ophthalmic steroids are allowed
  • Has a known history of active TB (Bacillus tuberculosis)
  • History of or high suspicion of Gilbert’s disease (safety run-in, Part B only)
  • Hypersensitivity to pembrolizumab or any of its excipients
  • Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier
  • Documented progression on and/or intolerance/hypersensitivity to both paclitaxel and irinotecan (Part B only)
  • Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; * NOTE: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study * NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy * Concurrent somatostatin analog therapy is allowed (for control of hormone excess) provided patient has been on stable dose for at least two months and tumor progression has been documented * Continuation of androgen deprivation therapy (ADT) allowed for patients with neuroendocrine prostate cancer (in the setting of castration-resistant prostate cancer, CRPC)
  • Has a known additional malignancy that is progressing or requires active treatment; exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks and any neurologic symptoms have returned to baseline), they have no evidence of new or enlarging brain metastases (confirmed by imaging within 28 days [d] of the first dose of trial treatment), and they are not using steroids for at least 7 days prior to trial treatment; this exception does not include carcinomatous meningitis which is excluded regardless of clinical stability
  • Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); * Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Has a history of (non-infectious) pneumonitis (interstitial lung disease) that required steroids or current pneumonitis
  • Has an active infection requiring systemic therapy
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
  • Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
  • Has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected)
  • Has received a live vaccine within 30 days of planned start of study therapy; NOTE: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed

Locations & Contacts

California

San Francisco
UCSF Medical Center-Mount Zion
Status: Active
Contact: Emily K. Bergsland
Phone: 415-514-6520
Email: Emily.Bergsland@ucsf.edu

Massachusetts

Boston
Dana-Farber Cancer Institute
Status: Active
Contact: Jennifer Ang Chan
Phone: 617-632-6315
Email: jang@partners.org

New York

New York
Memorial Sloan Kettering Cancer Center
Status: Active
Contact: Nitya P. Raj
Email: rajn@mskcc.org

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. To evaluate the best overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by investigator of pembrolizumab or pembrolizumab plus chemotherapy in subjects with previously treated poorly differentiated neuroendocrine carcinoma.

SECONDARY OBJECTIVES:

I. To determine the safety and tolerability of pembrolizumab-based therapy in this patient population.

II. To evaluate duration of response (DOR) in patients receiving pembrolizumab or pembrolizumab plus chemotherapy.

III. To evaluate progression free survival (PFS) in subjects treated with pembrolizumab or pembrolizumab plus chemotherapy (median PFS and 18 week [wk] PFS).

IV. To evaluate overall survival (OS) in subjects receiving pembrolizumab or pembrolizumab plus chemotherapy.

EXPLORATORY OBJECTIVES:

I. To compare ORR, DOR, and PFS based on immune-related Response Evaluation Criteria in Solid Tumors (irRECIST) with the same measures assessed by RECIST 1.1.

II. To correlate clinical outcomes (ORR, DOR, PFS, OS) with baseline immune cell infiltration, T cell receptor (TCR) repertoires and PD-L1 staining in pre-treatment tumor biopsies.

III. To assess baseline circulating immune cell profile and T-cell receptor (TCR) repertoires and changes with treatment, and correlate baseline and turnover of repertories to clinical outcomes.

IV. To analyze the relationship between baseline tumor proliferative index (as measured by Ki67) and response to therapy.

V. To examine the relationship between the tumor mutation profile/burden and response to therapy.

VI. To explore changes in circulating TCR profiles and circulating immune cells in patients treated with pembrolizumab alone compared to patients treated with pembrolizumab plus chemotherapy.

OUTLINE:

PART A: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.

PART B: Patients receive pembrolizumab IV over 30 minutes on day 1 and irinotecan IV over 90 minutes on days 1 and 8 -OR- paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then every 12 weeks thereafter.

Trial Phase & Type

Trial Phase

Phase II

Trial Type

Treatment

Lead Organization

Lead Organization
UCSF Medical Center-Mount Zion

Principal Investigator
Emily K. Bergsland

Trial IDs

Primary ID 169524
Secondary IDs NCI-2017-01728, 17-21843
Clinicaltrials.gov ID NCT03136055